市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | Onconetix, Inc. | - | - |
AIStockmoo 评分
| 价值 35% | -5.0 |
| AI Insight 参考 | NA |
| 相对估值 参考 | NA |
| 财务健康 参考 | -5.0 |
| 时机 35% | -0.2 |
| AI Technical 参考 | NA |
| 技术振荡指标 参考 | -2.0 |
| 技术平均移动指标 参考 | 2.5 |
| 聪明钱 30% | 0.0 |
| 分析师共识 参考 | 0.0 |
| 内部交易活动 参考 | NA |
| 市场环境 | ×1.21 |
| 宏观环境 参考 | -3.3 |
| 行业对比大市 (6个月) | -17.9% |
| 支柱一致性 | ×1.25 |
| 不计入评分 | |
| 价格波动 参考 | -0.2 |
| 最终评分 | -2.76 |
|
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative solutions for men’s health and oncology. It has a product named Entadfi an FDA-approved once-daily oral therapeutic for the treatment of benign prostatic hyperplasia, a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 57.97% |
| 机构持股比例 | 0.82% |
投资组合